<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01653314</url>
  </required_header>
  <id_info>
    <org_study_id>DW_MGV001</org_study_id>
    <nct_id>NCT01653314</nct_id>
  </id_info>
  <brief_title>Megavec 400 mg (Imatinib Mesylate) in Healthy Adult Male Volunteers</brief_title>
  <official_title>A Randomized, Open-label, Single Dose, 2-Treatment, 2-Period, 2-Way Crossover Study to Assess Safety and Pharmacokinetics of Megavec 400 mg (Imatinib Mesylate) Under Fasted Conditions in Healthy Male Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Daewoong Pharmaceutical Co. LTD.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Daewoong Pharmaceutical Co. LTD.</source>
  <brief_summary>
    <textblock>
      The purpose of this Study is to Assess Safety and Pharmacokinetics of megavec 400 mg
      (Imatinib mesylate) under Fasted Conditions in Healthy Male Subjects.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2012</start_date>
  <completion_date type="Actual">March 2012</completion_date>
  <primary_completion_date type="Actual">March 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety</measure>
    <description>Adverse events, Physical exam, Vital sign, Laboratory, 12-lead-ECG</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics</measure>
    <description>AUC and Cmax in plasma</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Megavec</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Glivec</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Megavec</intervention_name>
    <arm_group_label>Megavec</arm_group_label>
    <arm_group_label>Glivec</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Glivec</intervention_name>
    <arm_group_label>Megavec</arm_group_label>
    <arm_group_label>Glivec</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        -  Inclusion Criteria:

               -  Healthy and male subjects aged 20 to 55 years

               -  The subject has a Body weight ≥55 kg and ideal body weight (IBW) within ±20%

               -  A Subject who was judged to be healthy by the investigator to participate in this
                  study based on screening results (according to standard reference index updated
                  recently)

               -  A subject who provided written informed consent to participate in this study and
                  cooperative with regard to compliance with study related constraints.

          -  Exclusion Criteria:

               -  A subject with sign or symptoms or previously diagnosed disease of respiratory,
                  cardiovascular, endocrinology, liver, kidney, hematology, neurology and
                  psychology function or other significant diseases and history

               -  Known allergy or hypersensitivity to the study medication

               -  AST or ALT greater than 1.25 times the upper limit of reference range or Total
                  bilirubin greater than 1.25 times the upper limit of reference range base on
                  screening results

               -  A subject judged ineligible by the investigator to participate in this study for
                  other reason containing clinical laboratory tests
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <verification_date>July 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 25, 2012</study_first_submitted>
  <study_first_submitted_qc>July 26, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 31, 2012</study_first_posted>
  <last_update_submitted>July 26, 2012</last_update_submitted>
  <last_update_submitted_qc>July 26, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 31, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Imatinib Mesylate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

